Drug intelligence / Profile preview

STLR-201

Development stage: Preclinical
Lead developer: Stellular Bio
Modality: Stem Cell Therapies → Cell Therapies
Administration: Ophthalmic

Overview

STLR-201 is an off-the-shelf, platelet-derived regenerative biologic (PRB) developed by Stellular Bio. It is derived from platelet-progenitor stem cells and is designed to provide a standardized, scalable, and cost-effective alternative to autologous platelet-rich plasma (PRP) therapies. The candidate is primarily being developed for the treatment of dry eye associated with Sjogren's disease, aiming to leverage the regenerative and anti-inflammatory properties of platelet-derived growth factors and cytokines to restore ocular surface health and promote tissue repair.

Beyond the preview

Go deeper on STLR-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STLR-201.

Explore the full profile